CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents (NASDAQ: CTSO) and Converge Biotech have announced a strategic partnership to expand their market reach in India's sepsis and critical care markets. CytoSorbents' flagship product, CytoSorb, a blood purification technology that reduces cytokine storm and inflammatory toxins, will be distributed through Converge Biotech's extensive critical care sales network. CytoSorb, currently used in 76 countries with over 250,000 treatments administered, treats conditions like sepsis, septic shock, lung failure, acute liver disease, and trauma. The partnership aims to improve patient outcomes across Indian hospitals and ICUs by combining CytoSorbents' innovative technology with Converge's established critical care presence.
CytoSorbents (NASDAQ: CTSO) e Converge Biotech hanno annunciato una partnership strategica per espandere la loro presenza nel mercato indiano per il sepsi e le cure critiche. Il prodotto di punta di CytoSorbents, CytoSorb, una tecnologia di purificazione del sangue che riduce la tempesta di citochine e le tossine infiammatorie, sarà distribuito attraverso l'ampia rete di vendita di Converge Biotech nel settore delle cure critiche. CytoSorb, attualmente utilizzato in 76 paesi con oltre 250.000 trattamenti somministrati, tratta condizioni come sepsi, shock settico, insufficienza polmonare, malattia epatica acuta e traumi. La partnership mira a migliorare i risultati per i pazienti negli ospedali e nelle unità di terapia intensiva indiane, combinando la tecnologia innovativa di CytoSorbents con la presenza consolidata di Converge nelle cure critiche.
CytoSorbents (NASDAQ: CTSO) y Converge Biotech han anunciado una asociación estratégica para expandir su alcance en el mercado de sepsis y cuidado crítico en India. El producto insignia de CytoSorbents, CytoSorb, una tecnología de purificación de sangre que reduce la tormenta de citoquinas y las toxinas inflamatorias, se distribuirá a través de la extensa red de ventas de cuidado crítico de Converge Biotech. CytoSorb, que actualmente se utiliza en 76 países con más de 250,000 tratamientos administrados, trata condiciones como sepsis, shock séptico, falla pulmonar, enfermedad hepática aguda y trauma. La asociación tiene como objetivo mejorar los resultados de los pacientes en hospitales y UCI indias al combinar la tecnología innovadora de CytoSorbents con la presencia establecida de Converge en el cuidado crítico.
사이토소르벤트 (NASDAQ: CTSO)와 컨버지 바이오텍은 인도의 패혈증 및 중환자 치료 시장에서 시장 점유율을 확장하기 위한 전략적 파트너십을 발표했습니다. 사이토소르벤트의 주력 제품인 사이토소르브는 사이토카인 폭풍과 염증 독소를 줄이는 혈액 정화 기술로, 컨버지 바이오텍의 방대한 중환자 판매 네트워크를 통해 유통될 예정입니다. 현재 76개국에서 사용되며 250,000회 이상의 치료가 시행된 사이토소르브는 패혈증, 패혈성 쇼크, 폐 기능 상실, 급성 간 질환 및 외상과 같은 상태를 치료합니다. 이 파트너십은 사이토소르벤트의 혁신적인 기술과 컨버지의 중환자 치료에서의 확립된 존재를 결합하여 인도의 병원과 중환자실에서 환자 결과를 개선하는 것을 목표로 하고 있습니다.
CytoSorbents (NASDAQ: CTSO) et Converge Biotech ont annoncé un partenariat stratégique pour élargir leur portée sur le marché indien de la sepsie et des soins critiques. Le produit phare de CytoSorbents, CytoSorb, une technologie de purification du sang qui réduit la tempête de cytokines et les toxines inflammatoires, sera distribué via le vaste réseau de vente de soins critiques de Converge Biotech. CytoSorb, utilisé actuellement dans 76 pays avec plus de 250 000 traitements administrés, traite des conditions telles que la sepsie, le choc septique, l'insuffisance pulmonaire, les maladies hépatiques aiguës et les traumatismes. Ce partenariat vise à améliorer les résultats des patients dans les hôpitaux et les services de soins intensifs indiens en combinant la technologie innovante de CytoSorbents avec la présence établie de Converge dans les soins critiques.
CytoSorbents (NASDAQ: CTSO) und Converge Biotech haben eine strategische Partnerschaft angekündigt, um ihre Marktpräsenz im Bereich Sepsis und Intensivpflege in Indien zu erweitern. Das Flaggschiffprodukt von CytoSorbents, CytoSorb, eine Blutreinigungstechnologie, die den Zytokinsturm und entzündliche Toxine reduziert, wird über das umfangreiche Vertriebsnetz von Converge Biotech im Bereich der Intensivpflege vertrieben. CytoSorb, das derzeit in 76 Ländern mit über 250.000 durchgeführten Behandlungen eingesetzt wird, behandelt Erkrankungen wie Sepsis, septischen Schock, Lungenversagen, akute Lebererkrankungen und Traumata. Das Ziel der Partnerschaft ist es, die Ergebnisse für Patienten in indischen Krankenhäusern und Intensivstationen zu verbessern, indem die innovative Technologie von CytoSorbents mit der etablierten Präsenz von Converge im Bereich der Intensivpflege kombiniert wird.
- Strategic expansion into India's fast-growing critical care market
- Access to Converge Biotech's extensive critical care sales force and hospital network
- Product has proven track record with 250,000+ treatments administered across 76 countries
- None.
Insights
This strategic partnership represents a significant market expansion opportunity in India's rapidly growing critical care sector. The collaboration leverages Converge Biotech's established distribution network and sales force to accelerate CytoSorb's market penetration in a country where sepsis and critical care needs are substantial. With more than 250,000 CytoSorb treatments administered globally across 76 countries, this partnership could drive meaningful revenue growth in one of the world's largest healthcare markets.
India's critical care market presents substantial growth potential due to its large population, increasing healthcare infrastructure and rising incidence of sepsis and other critical illnesses. Converge Biotech's existing ICU portfolio and strong hospital relationships provide immediate access to key decision-makers, potentially accelerating CytoSorb's adoption rate. The synergistic product portfolio approach could lead to faster market penetration and increased sales efficiency.
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio.
CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that reduces “cytokine storm” and a broad range of inflammatory toxins that can otherwise lead to massive inflammation, organ failure and death in many critical illnesses that are very common in India such as sepsis and septic shock, lung failure, acute liver disease, trauma, burn injury, pancreatitis, and others. The therapy is also used to treat acute liver disease and trauma through the removal of harmful substances such as bilirubin and myoglobin, respectively. CytoSorb is used in 76 countries worldwide with more than a quarter million treatments administered to date.
Converge Biotech will leverage its extensive critical care sales force and strong hospital network to accelerate CytoSorb's market penetration in India, ensuring more healthcare facilities have access to this critical therapy. In doing so, CytoSorb will help Converge Biotech strengthen its existing intensive care unit (ICU) portfolio to now include the treatment of sepsis and other life-threatening diseases. With CytoSorbents' innovative technology and Converge's established critical care presence, the two companies plan to expand the availability of life-saving blood purification products to healthcare professionals throughout India, with the goal of improved patient outcomes in hospitals and ICUs across the country.
"We look forward to a great collaboration with Converge Biotech to make CytoSorb more broadly available to physicians across India to treat complex diseases like septic shock, acute respiratory distress syndrome, liver failure and many others," said Dr. Phillip Chan, Chief Executive Officer at CytoSorbents. "With our unique therapy and Converge Biotech’s local expertise, distribution capabilities, relationships within the Indian healthcare market, focused critical care sales team, complementary therapy portfolio, and market strength, we believe this partnership can help drive the growth of both companies for years to come in one of the fastest-growing critical care markets globally.”
"We are extremely excited to join forces with CytoSorbents and make CytoSorb therapy accessible to patients who urgently need it in India, helping to save more lives," said Arunkumar Bijjala, Managing Director of Converge Biotech. "Our mission has always been to provide innovative and life-saving therapies in the critical care space, and CytoSorb represents a highly impactful solution for sepsis and other critical illnesses that are major challenges for physicians in the ICU. This partnership will allow us to significantly expand our offerings and reinforce our position as a leading player in the critical care segment."
The collaboration signifies a new chapter, empowering both organizations to drive the adoption of advanced therapies for critical illnesses in India.
About Converge Biotech
Converge Biotech is a fast-growing pharmaceutical company in India specializing in the critical care segment. With a strong presence in ICU settings, Converge is committed to bringing innovative, life-saving therapies to patients in India and improving patient care outcomes.
For more information on Converge, please visit www.convergebio.in
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.
CytoSorbents’ lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.
In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.
The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s website at www.cytosorbents.com or follow us on Facebook and X.
CytoSorbents Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
CytoSorbents Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com
CytoSorbents Investor Relations Contact:
Aman Patel, CFA
ICR-Westwicke
ir@cytosorbents.com
Converge Biotech Media Contact
Mr. Eswar Teja, Product Manager
+91 99485 12050
FAQ
What is the purpose of CytoSorbents (CTSO) partnership with Converge Biotech in India?
How many countries currently use CytoSorb (CTSO) blood purification technology?
What medical conditions does CytoSorb (CTSO) treat in India?
